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ABSTRACT
Background. Rituximab has been used in antineutrophil cyto-
plasmic antibody (ANCA)-associated vasculitis (AAV) since
2003. Our objective was to describe outcomes and adverse events
following rituximab since that time in an inception cohort.
Methods. Patients with AAV (diagnosed 1991–2012) who re-
ceived rituximab (n = 120) were evaluated and incidence per
person-year (PPY) with 95% confidence interval was calcu-
lated for relapse and infections. Time to remission and relapse
by number of rituximab infusions given per treatment course
(≤2 versus >2) and by ever having been exposed to cyclophos-
phamide were compared using Kaplan–Meier curves. Rituxi-
mab-treated patients were characterized in comparison with
AAV patients treated with cyclophosphamide but not exposed
to rituximab (n = 351) using Fisher’s exact or rank tests.
Results. Rituximab resulted in 86% achieving remission and
41% having a subsequent relapse in a median of 19 months
(range 9–29). Time to remission and relapse were similar
between rituximab infusion courses (≤2 versus >2; remission
P = 0.86 and relapse P = 0.78, respectively). Incidence of
relapse was 0.22 PPY (0.14, 0.31) and of severe infection was
0.12 PPY (0.08, 0.24). Time to relapse was shorter in those
never exposed to cyclophosphamide (n = 20): 50% by 8 months
versus 50% by 24 and 30 months for those with prior or concur-
rent exposure to cyclophosphamide (n = 100). Compared with
those who never received rituximab, rituximab-treated patients
were younger (P < 0.001), more likely to have granulomatosis
with polyangiitis (P = 0.001) and had more upper airway (P =
0.01) and less kidney involvement (P = 0.007).
Conclusions. Rituximab is beneficial when prescribed outside
of a trial setting. Response to treatment and relapse is similar
regardless of infusion number. Rituximab without cyclophos-
phamide may result in a shorter time to relapse supporting
combination of these therapies.
Keywords: ANCA, glomerulonephritis, immunosuppression,
outcomes, relapse
INTRODUCTION
In the 1970s, the addition of cyclophosphamide to gluco-
corticoid therapy for the treatment of small-vessel vasculitis
resulted in a dramatic reduction in mortality in what was then
an often fatal disease [1]. Cyclophosphamide has remained the
mainstay of induction therapy [2–5] for what is now called
antineutrophil cytoplasmic autoantibody (ANCA)-associated
vasculitis (AAV). Because ANCA are pathogenic, there has
been much interest in the use of anti-B-cell drugs in AAV.
Studies reporting efficacy of rituximab in treatment-resistant
AAV began over a decade ago [6–11]. More confidence in the
effectiveness of rituximab came with two randomized control
trials demonstrating the non-inferiority of rituximab to cyclo-
phosphamide for induction therapy [12–14]. There are studies
that support the use of rituximab with cyclophosphamide
therapy for induction of remission [12, 15] and other literature
that supports the use of rituximab and corticosteroids without
cyclophosphamide [13, 14].
In 2003, our vasculitis center aimed to enroll at least 100
consecutive patients in whom rituximab was being administered
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into a cohort study. While randomized trials are essential for
comparisons of treatment regimens, this type of inception
cohort has the advantage of including those from the ‘real world’
and permits follow-up from the time of initial diagnosis until
death. In this setting, we present data on the types of patients re-
ceiving rituximab, methods of administration and associated




Patients from the Glomerular Disease Collaborative
Network (GDCN) inception cohort [16–18] were included in
this study if they had AAV and received rituximab at any point
during their treatment course. The GDCN is comprised of
private practice and tertiary medical center nephrologists pri-
marily located in North Carolina and throughout the south-
eastern United States. We aimed to prospectively study at least
100 consecutive patients in whom rituximab was given begin-
ning 15 March 2003. We enrolled and followed 120 patients
through 9 October 2012. Entry criteria for this inception cohort
have been previously described [16, 17]. Patients required
diagnostic biopsy and/or a positive ANCA determination
by immunofluorescence (IF) microscopy or antigen-specific,
enzyme-linked immunosorbent assay (ELISA) and/or a strong
clinical indication of AAV [19], as well as treatment at any
time during their course with rituximab. Age and peak serum
creatinine were collected at the time of initial diagnosis.
Patients who had end-stage kidney disease (ESKD) at the time
of presentation were excluded from this study.
Diagnostic disease categories were defined according to the
modified Chapel Hill Consensus Conference nomenclature
[20–23]. A diagnosis of granulomatosis with polyangiitis (GPA),
microscopic polyangiitis (MPA), eosinophilic granulomatosis
with polyangiitis, or pauci-immune necrotizing and/or crescentic
glomerulonephritis (GN) without overt signs of systemic vascu-
litis were determined by previously described criteria [16, 17].
Definitions of remission, relapse and treatment resistance have
been previously described [24]. Specifically, remission was
defined as the absence of dysmorphic red blood cells and red
blood cell casts on microscopic urinalysis or findings of focal
sclerosing glomerulopathy without active crescents or necrosis
on kidney biopsy and the absence of extra-renal manifestations
of vasculitis. Proteinuria alone was not considered indicative
of active GN. Severe infections were defined as any infection
requiring intravenous antibiotics, hospitalization or resulting in
an infection-related death. ‘Concurrent’ cyclophosphamide was
defined as rituximab and cyclophosphamide both given for
active disease prior to reaching a state of remission. ‘Previous’
cyclophosphamide was defined as administration of cyclophos-
phamide followed by achieving a state of remission. Rituximab
administration was given only after achieving a state of remis-
sion in previous cyclophosphamide.
Patient participation was approved by the University of
North Carolina Institutional Review Board (IRB), with in-
formed consent provided by all patents for long-term follow-up.
Patient groups
Rituximab was used in 120 patients in a variety of situations
including with or without cyclophosphamide or other immuno-
suppressive drugs at the time of induction or disease relapse,
because of cyclophosphamide resistance, or with the aim to
maintain disease remission (Figure 1). To understand differ-
ences in those who did and did not receive rituximab, we com-
pared the rituximab-treated patients with 351 AAV patients
enrolled in our inception cohort since 1991 who were treated
with cyclophosphamide but who never received rituximab.
Therapy
All therapeutic immunosuppressive interventions were re-
corded. Patients who had received at least 1 infusion of rituxi-
mab were considered to have been treated with rituximab.
Patients who received at least 1 intravenous (IV) dose of cyclo-
phosphamide or 1 month of oral cyclophosphamide were con-
sidered to have been treated with cyclophosphamide.
Rituximab was administered according to two separate
dosing regimens based on physician preference: 1 g of rituxi-
mab on Days 1 and 15, or 375 mg/m2 body surface area
weekly for 4 weeks.
Statistical analysis
Descriptive statistics included the number (n), percentage
(%), mean and standard deviation (SD) [or median and inter-
quartile range (IQR)]. Comparisons between groups used
Fisher’s exact tests for categorical measures and Wilcoxon
rank-sum tests or Kruskal–Wallis tests for continuous mea-
sures. Incidence rates were reported for relapse and infection
as per patient-year of follow-up using all events, with a
Poisson distribution used to calculate 95% confidence intervals
(95% CI) and SDs. Kaplan–Meier estimators were used to plot
the univariate probability of time to each outcome. Time ‘0’
was defined as the date of first rituximab infusion or start date
of any therapy, as appropriate. Proportional hazards models
were used for multivariable modeling of time to ESKD or
death, with hazards ratio, 95% CI and P values presented.
Analyses were conducted using SAS software (version 9.3 SAS
Institute, Cary, NC). Exact P values were reported with a two-
sided P value of <0.05 considered statistically significant.
RESULTS
Demographics
In the 120 patients who received rituximab, 166 courses
were given to 100 patients who had previously or concurrently
received cyclophosphamide [for a median of 6 months cyclo-
phosphamide (range 1–45 months; IQR 4.5–11.1 months)],
and 34 courses of rituximab were given in 20 patients who had
no previous or concurrent exposure to cyclophosphamide
(Figure 1).
Table 1 presents demographics of those who received ritux-
imab without exposure to cyclophosphamide throughout
treatment course (n = 20), those who were treated with rituxi-
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time (n = 100) and those who were treated with cyclophospha-
mide and never received rituximab (n = 351). Compared with
cyclophosphamide-treated patients who never received rituxi-
mab, patients who received rituximab were a decade younger,
more likely to be diagnosed with GPA, and had more disease
involvement of the upper airways but less of the kidney. Pa-
tients who received rituximab were followed almost twice as
long as those who never received rituximab (almost 5 versus
2.5 years, P < 0.0001) and were also generally exposed to more
months of any type of immunosuppressant. Although longer
duration of therapy is expected with longer follow-up, in the
rituximab-treated patients, more treatment likely also repre-
sents the need for management of ongoing or recurring
disease activity. Because of the many differences between
those who did and did not receive rituximab, further compari-
sons of the impact of treatment on outcomes between these
non-randomized treatment groups was not informative and is,
therefore, not presented.
Rituximab therapy administration
Of the 120 rituximab-treated patients, the first course was
intended to be administered as 1 g on Days 1 and 15 in 101 pa-
tients, as 375 mg/m2 weekly for four doses in 15 patients, and
the number of doses was undocumented in 5 patients. Infu-
sion numbers of ≤2 infusions versus >2 infusions were com-
pared with account for the few patients who did not receive all
intended infusions. Time to remission and time to relapse
were similar in the two dosing regimens (remission P = 0.8608,
Figure 2A; relapse P = 0.7806, Figure 2B).
Sixty-five (33%) of the 200 treatments of rituximab were
given concurrently with cyclophosphamide. Thirty-four (17%)
were given without prior exposure to cyclophosphamide.
Ninety-nine (50%) of the courses of rituximab were given with
a patient history of prior cyclophosphamide exposure but
without concurrent cyclophosphamide exposure. Time to
relapse was shorter in patients who had never been exposed
cyclophosphamide (Figure 3). Patients who received rituximab
but did not receive cyclophosphamide included more female
patients, more ANCA-negative patients and less PR3-ANCA
patients, with less renal and more pulmonary involvement.
The patients who only received rituximab had less of the trad-
itional risk factors for relapse (PR3-ANCA and pulmonary
involvement). There was no difference in the months of ster-
oids preceding remission or relapse in the groups (Table 2).
Twenty-one courses of rituximab were given to 17 patients for
remission maintenance (Figure 1).
Of the 200 courses of rituximab, 6 courses of rituximab did
not result in B-cell depletion (rituximab dosed as 1 g given ×1
in one case, 1 g given ×2 in four cases and 375 mg/m2 weekly
×4 in one case). B cells were not tested for depletion in 24 cases.
Remission and relapse following rituximab therapy
Of the 120 patients who received rituximab, 103 (86%)
achieved remission with 42 (41%) having a subsequent relapse
F IGURE 1 : Treatment groups. Single asterisk denotes 65 of the 166 courses of rituximab were given during the same flare as cyclophospha-
mide. Double asterisk denotes in 43 of the courses of rituximab, cyclophosphamide was co-administered for treatment of disease relapse. In 80
of the courses, rituximab was given for disease flare without concurrently giving cyclophosphamide. Hash denotes information included on first
course of rituximab only. Data missing on one person in this group. Double hash denotes information included on first course of rituximab
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in a median of 19 (9, 25) months. Of the patients who achieved
remission with rituximab therapy 3% required an additional
course of rituximab to finally achieve adequate remission.
There was no difference in time to remission or time to relapse
between MPO-ANCA, PR3-ANCA and ANCA-negative pa-
tients (remission P = 0.43; relapse P < 0.08), suggesting a trend
for the ANCA-negative patients to relapse sooner. In ANCA-
positive patients, ANCA titers increased more than 5 units/mL
at the time of relapse from prior levels in 64/130 (49%) cases.
ANCA titers were stable or decreased from prior levels at the
time of relapse in 66/130 (51%) cases.
Rituximab was originally given for four indications: 17
(14%) were treated for new onset disease, 18 (15%) were given
rituximab for new onset disease that was treatment resistant to
cyclophosphamide, 70 (58%) received rituximab for relapse and
14 (12%) were given rituximab for relapse treatment resistant to
cyclophosphamide (Table 3). One patient received a first course
of rituximab for remission maintenance after having been given
cyclophosphamide for induction therapy and then found to
be unable to tolerate azathioprine or mycophenolate mofetil
(MMF) for remission maintenance (excluded from Table 3).
When comparing the groups of patients who received their first
course of rituximab for differing indications, there was a higher
proportion of males who received rituximab for new diagnosis
of AAV than for treatment resistance to cyclophosphamide
(Table 3). Race and disease category were not different across
the groups receiving rituximab for differing reasons (Table 3)
but there was a greater proportion of patients with PR3-ANCA
and lung involvement who received rituximab for a relapse than
for treatment resistance to cyclophosphamide (Table 3). There
was no significant difference across groups in the percentage of
patients achieving remission on therapy or complete remission
Table 1. Demographics
Presented as percent unless otherwise
noted
Rituximab, no




rituximab) (n = 351)
P value*
Age (years), median (IQR) 50 (38, 64) 50 (35, 58) 60 (47, 71) <0.001
Female 75% 49% 46% 0.81
Race 0.99
White 79% 83% 86%
Black 16% 8% 9%
Other 5% 9% 5%
ANCA 0.12
MPO/pANCA 15% 42% 56%
PR3/cANCA 40% 56% 42%
Both PR3 and MPO 5% 1% 0
ANCA positive (MPO) 0% 2% 1%
PR3 not known
ANCA negative 40% 10% 1%
Disease category 0.001
MPA 40% 44% 54%
GPA 55% 45% 22%
GN 5% 9% 23%
EGPA 0% 2% 1%
Lung involvement 10% 57% 51% 0.23
ENT involvement 35% 53% 35% 0.01
Kidney involvement 45% 85% 97% 0.007
Creatinine peak at diagnosis 1.2 (1.0, 2.0) 1.9 (1.1, 2.9) 3.4 (2.0, 5.4) 0.0001






































































Follow-up since first day of any
immunosuppression median (IQR)
(months)
18 (7, 49) 59 (40, 104) 31 (12, 59) 0.001
IQR, interquartile range; MPO, myeloperoxidase; ANCA, antineutrophil cytoplasmic antibody; PR3, proteinase 3; MPO, microscopic polyangiitis; GPA, granulomatosis
with polyangiitis; GN, pauci-immune necrotizing and/or crescentic glomerulonephritis; EGPA, eosinophilic granulomatosis with polyangiitis; ENT, ear, nose and throat;
CYC, cyclophosphamide; MMF, mycophenolate mofetil; AZA, azathioprine; CI, confidence interval; NA, not applicable.
*P values compare all rituximab treated (n = 120) to those who never received rituximab (n = 351) and were calculated by Fisher’s exact test for categorical variables and Wilcoxon
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off therapy, time to remission on therapy or complete remission
off therapy, or the percentage who had disease relapse (Table 3).
In the three patients who received rituximab for induction
therapy and subsequently relapsed, there was a significantly
shorter time to relapse than the time to relapse for patients
who received rituximab for other indications (mean 4 ± 1
months, P = 0.012) (Table 3).
Twenty-one patients went into complete remission and came
off all therapy; of these, all had documented B-cell return. There
were no distinguishing features among these patients in terms of
type of ANCA or organ involvement.
Multiple courses of rituximab for treatment of relapse
Of the 45 patients who had a second treatment with ri-
tuximab, 38 (84%) achieved remission again and 12 (32%)
subsequently relapsed in a median of 20 (12, 24) months.
The median time between the first and second rituximab
courses was 19 months (IQR 11, 31). Thirty-three (73%)
had no further relapse over the median follow-up time of
9 (5, 16) months. Five (11%) of the 45 achieved complete
remission.
A third course of rituximab was given to 18 patients. Four-
teen (78%) achieved remission on therapy and 3 (17%)
F IGURE 2 : Frequency of rituximab dosing does not affect time to remission or time to relapse. Shown are Kaplan–Meier curves depicting time
to remission on therapy for patients who received 2 infusions of rituximab compared with patients who received >2 infusions of rituximab
(A) or time to relapse for patients who received 2 infusions of rituximab compared with patients who received >2 infusions of rituximab (B).
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achieved complete remission and stopped all therapy. Six
patients relapsed following the third rituximab course in a
median of 22 (16, 33) months. A fourth course of rituximab
was given to 10 patients, a fifth course to 3 patients, a sixth
course to 2 patients and 1 person had 8 courses of rituximab.
The median time between rituximab courses over all was
20 months (IQR 11, 29).
In all patients who received repeated rituximab courses, the
dose given was 1 g ×2 separated by 14 days except for the fol-
lowing: two instances of the second course of rituximab given
1 g ×1, one instance in a third course of rituximab when 375
mg/m2 was given weekly ×4 and once when 1 g was given ×1,
one instance in a fourth course of rituximab when 1 g was
given ×1 and one instance in a sixth course of rituximab when
1 g was given ×1.
B-cell repopulation data were available in 50 patients and
66 courses of rituximab used following previous rituximab
administration. In 58/66 courses, B-cell repopulation was
documented. In all of these courses, relapse occurred in a
median of 10.5 (IQR 5, 19.5) months following B-cell repopu-
lation date. Relapses occurred in 8/66 instances when B cells
were documented as being depleted.
Immunosuppression in addition to rituximab
Median months of total prednisone treatment in the cohort
was 11 (5, 25) months which included prednisone given with
induction therapy and for treatment of relapse. One hundred
and four (87%) patients were at some point treated with
methylprednisolone with a median of 5 (3, 6) infusions. One
hundred (83%) patients were exposed to cyclophosphamide
for a median of 7 (5, 13) months. Ninety (75%) patients were
treated for a median of 21 (5, 55) months with MMF and 64
(53%) patients received a median of 8 (2, 26) months of
azathioprine.
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In the time period following a patient’s first rituximab infu-
sion, 72 (60%) patients were treated for a median of 5 (3, 13)
months with prednisone; 33 (28%) patients were treated for a
median of 3 (1, 5) months with cyclophosphamide; 38 (32%)
patients were treated for a median of 20 (4, 48) months with
MMF; and 34 (28%) patients were treated for a median of 6 (1,
26) months with azathioprine.
Adverse events
Adverse events following immunosuppression with rituxi-
mab or rituximab and cyclophosphamide are listed in Table 4.
Follow-up was different between these two groups (Table 1).
Infectious prophylaxis therapy was given in conjunction with
rituximab in 52/120 (43%) of patients and trimethoprim sulfa-
methaxazole was used almost exclusively. Of the 120 rituxi-
mab-treated patients, 18 (15%) had no infections and 102
(85%) patients experienced a total of 410 infections. Most
common infections included upper respiratory (29% of all in-
fections) and pulmonary (27%), followed by urinary tract/
pyelonephritis (11%), systemic or organ threatening (7%) and
viral infections (5%).
Of the 120 rituximab-treated patients, there were 18
cancers following immunosuppression: 7 non-melanoma skin
cancers, 1 gynecologic, 2 colon, 2 bladder, 2 hematologic,
1 prostate and 3 renal cell carcinomas (Table 4).
Among the 120 patients who received rituximab, late-onset
neutropenia, defined as an absolute neutrophil count ≤1.5 × 109
[26] was noted in 16 (13%) patients with a mean onset of 226
days following first rituximab infusion and a range of 60–1149
days. Only 2 of these 16 patients had neutropenia >1 year fol-
lowing first rituximab dose.
DISCUSSION
Over 10 years of experience prescribing rituximab in a variety
of clinical circumstances for treatment and management of
AAV shows us that the addition of rituximab to the arma-
mentarium of therapies aimed at controlling disease is asso-
ciated with reasonable safety profiles and beneficial effects.
Table 3. Indication and outcome for first treatment with rituximab (n = 119a)
New diagnosis, rituximab
induction (n = 17)
New diagnosis, CYC




resistance (n = 14)
*P
value
Female 10 (59%) 4 (22%) 42 (60%) 8 (57%) 0.03
MPO/pANCA 1 (6%) 7 (39%) 31 (44%) 5 (36%) 0.0006
PR3/cANCA 8 (50%) 9 (50%) 37 (53%) 9 (64%)
ANCA negative 6 (38%) 1 (6%) 2 (3%) 0
Both PR3 and MPO 1 (6%) 1 (6%) 0 0
Organ
Kidney 10 (59%) 16 (89%) 57 (81%) 10 (71%) 0.13
Lung 3 (18%) 9 (50%) 37 (53%) 10 (71%) 0.02
ENT 6 (35%) 5 (28%) 40 (57%) 8 (57%) 0.08
Remission off therapy 3 (18%) 2 (11%) 15 (21%) 1 (7%) 0.62













Relapse 3 (18%) 4 (22%) 30 (43%) 6 (43%) 0.14




























MPO, myeloperoxidase; ANCA, antineutrophil cytoplasmic antibody; PR3, proteinase 3; ENT, ear, nose and throat; ESKD, end-stage kidney disease.
*P values were calculated by Fisher’s exact test for categorical variables and Wilcoxon two-sample test for continuous variables.
aOne patient was given first course of rituximab as remission maintenance, so the table includes 119 instead of 120 patients.
Table 2. Characteristics by exposure to cyclophosphamide (CTX) (n = 120)









Female 75% 60% 38%
ANCAType <0.0001
MPO/P—ANCA 15% 56% 31%
PR3/C—ANCA 40% 44% 67%
ANCA negative 40% 0% 2%
PR3- and MPO-ANCA2 5% 0% 0%
Organ
Lung 10% 51% 62% 0.0002
ENT 35% 49% 55% 0.34
Kidney 45% 73% 64% 0.99
Months of prednisone prior
to remission, n/N
13/20 27/43 34/55 0.11
Median (IQR) 4.8 (3, 8.9) 10.9 (9, 30) 10.5 (3.9, 19)
Months of prednisone prior
to first relapse, n/N






Deaths 5% 5% 9% 0.63
CTX, cyclophosphamide; ANCA, antineutrophil cytoplasmic autoantibodies;
MPO, myeloperoxidase; PR3, proteinase 3; P, perinuclear, cytoplasmic; C, cytoplasmic;
IQR, interquartile range.
*P values were calculated by Fisher’s exact test for categorical variables and Wilcoxon
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Our experience highlights the multiple uses of rituximab in
AAV including as primary immunosuppressant for induction,
in combination with cyclophosphamide as induction, as
primary immunosuppressant for relapse, in combination with
cyclophosphamide for relapse and as rescue therapy in cyclo-
phosphamide-resistant disease.
This cohort is unique in its inclusion of such varying
patient presentations. Our data reflect no difference in time to
remission and time to relapse regardless of whether clinicians
used ≤2 infusions of rituximab or >2 infusions of rituximab
for any given course. This has been an area of debate, specific-
ally regarding whether greater number of infusions allow for
improved B-cell depletion and longer time to relapse but, in
our population, this does not appear to be the case. Presence
of MPO-ANCA, PR3-ANCA or being ANCA-negative did not
impact time to remission or relapse.
Rituximab therapy in this study was administered in a
variety of circumstances during a time when clinicians were
still understanding how best to use this drug for AAV. It is
now known that rituximab is effective for induction therapy
[12–14] and relapse treatment [13] in AAV. However, relapse
is common following rituximab regardless of whether other
immunosuppression is withdrawn or maintained [11]. Due to
having only 20 patients who received rituximab without any
exposure to cyclophosphamide, this study has limited ability
to compare the impact of rituximab treatment in the absence
of cyclophosphamide therapy to treatment with both. Of
note, the cohort who never received cyclophosphamide had
less PR3-ANCA, more ANCA-negative patients and less lung
involvement but similar mortality.
The goal of treatment of AAV is to improve patient out-
comes while limiting therapy-related adverse events. There are
treatment regimens published which suggest effective use of
rituximab and cyclophosphamide together for achieving in-
duction of remission [12, 15]. Our data support this concept
although this study was not designed to compare treatment
strategies, and there are important differences in our studied
groups. Although we do not have an established protocol for
the co-administration of cyclophosphamide and rituximab,
the results of our study suggest the possibility of a therapeutic
approach in patients with AAV in which cyclophosphamide
and rituximab could be combined to broaden the disease
modifying immunosuppression while limiting toxicity by
dosage reduction of each given therapy. This concept has been
supported previously in the literature in a report of a rituxi-
mab based low-dose cyclophosphamide regimen which was ef-
fective in achieving long-term remission in AAV [27].
Although reports have been made in other retrospective
studies and case reports of the effectiveness and safety of rituxi-
mab in AAV [15, 25, 28, 29], our study was unique in that it has
close to 10 years of follow-up on a diverse patient group (MPA
and GPA, PR3- and MPO-ANCA-positive as well as ANCA-
negative patients). The strength of an inception cohort study
design is that a real-world clinical setting is utilized without ex-
clusion criteria, as is needed in a conventional treatment trial.
This can also be interpreted as a weakness, given the heteroge-
neous population with a variety of disease presentations, levels of
severity and differences in exposure to immunosuppression
outside of rituximab. For example, rituximab is becoming ac-
cepted by a growing number of clinicians as a means of lowering
glucocorticoid exposure and speeding complete glucocorticoid
discontinuation, but this was difficult to study in our inception
cohort as we do not have total glucocorticoid dose in all patients.
Likewise, we could not evaluate the impact of rituximab admin-
istration on lowering dosage of other immunosuppressants.
This study supports future development of multi-drug treat-
ment strategies in patients with vasculitis and randomized
control trials to evaluate the effectiveness and adverse event
profiles of these multi-drug regimens compared with rituximab
only or cyclophosphamide only immunosuppressant strategies.
This study adds to mounting evidence that rituximab and
cyclophosphamide can be used together for successful treat-
ment of AAV in patients with all varieties of disease categories,
ANCA specificities and disease presentations, including severe
renal injury. In this heterogenous population, use of cyclophos-
phamide and rituximab in sequence or in combination as
multi-drug strategies had reasonable safety profiles and was
therapeutically efficacious. Randomized control trials are re-
quired to prove if multi-drug strategies are more or less benefi-
cial than single-drug strategies.
In conclusion, rituximab has been used effectively in a real-
world population of AAV with MPO-ANCA, PR3-ANCA and
ANCA-negative disease for over 10 years. It has been shown to
be effective for new disease induction therapy both by itself
(along with corticosteroids) and in combination with cyclophos-
phamide and corticosteroids, as relapse therapy in similar
combinations, for cyclophosphamide-resistant disease and for
remission maintenance therapy. The use of 375 mg/m2 gives no
advantage with respect to achieving remission or preventing
relapse compared with 1 g ×2 separated by 14 days. Rituximab
and cyclophosphamide given during active disease prior to
attaining remission may allow for more sustained remission
than use of rituximab without cyclophosphamide. There is a



















0.12 (0.08, 0.24) 0.17 (0.13, 0.22) 0.63
Cancera, n (%) 0 18 (18%) 0.04
MI, n (%) 0 0 0.99
CVA, n (%) 0 1 (1%) 0.99
ESKD, n (%) 1 (5%) 9 (9%) 0.99
Death, n (%) 1 (5%) 7 (7%) 0.99
ESKD or death (%) 1 (5%) 14 (14%) 0.46
*P values were calculated by Fisher’s exact test for categorical variables and Wilcoxon
two-sample test for continuous variables.
CI, confidence interval; MI, myocardial infarction; CVA, cerebrovascular accident, ESKD,
end-stage kidney disease.
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population of patients who do not relapse following rituximab
administration and achieve remission off of immunosuppressive
therapy.
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